Cancer News

Many Late Stage Lung Cancer Patients do not Receive Treatment (01/24/2017)

A national study by researchers at UC Davis Comprehensive Cancer Center has found that a significant number of lung cancer patients are not receiving treatment. Based on data between 1998 and 2012 from the National Cancer Database, 21 percent of patients (190,539) with non-small cell lung cancer (NSCLC) received no specific cancer treatment, such as …

Continue reading "Many Late Stage Lung Cancer Patients do not Receive Treatment"

Keytruda Approved for First-Line Treatment of Select Patients with Advanced Non-Small Cell Lung Cancer (10/25/2016)

The US Food and Drug Administration (FDA) has approved Keytruda® (pembrolizumab) as a first-line treatment options for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors express high levels of PD-L1 without EGFR or ALK mutations. PD-1 is a protein that inhibits certain types of immune responses. Drugs that block PD-1, such as Keytruda … Continue reading "Keytruda Approved for First-Line Treatment of Select Patients with Advanced Non-Small Cell Lung Cancer"

Tecentriq® Improves NSCLC Survival Compared to Chemotherapy Regardless of PD-L1 Status (10/25/2016)

Tecentriq® (atezolizumab) improves the outcomes of individuals with advanced non-small cell lung cancer (NSCLC) according to the results of a pivotal clinical trial presented at the European Society of Medical Oncology (ESMO) 2016 Annual Meeting this week. Tecentriq is an agent that stimulates the immune system to recognize and mount an immune attack against cancer … Continue reading "Tecentriq® Improves NSCLC Survival Compared to Chemotherapy Regardless of PD-L1 Status"

Whole-Brain Radiotherapy Fails to Benefit Most Patients with Lung Cancer (09/13/2016)

Whole-brain radiotherapy (WBRT) provides “little additional clinically significant benefit” for patients with non–small cell lung cancer (NSCLC) with brain metastases, according to doctors performing the first large-scale randomized controlled trial of its kind. As many as 30% of all patients with NSCLC will present with or develop brain metastases. There is currently a routine practice … Continue reading "Whole-Brain Radiotherapy Fails to Benefit Most Patients with Lung Cancer"

First Targeted Therapy Shows Promise in Small Cell Lung Cancer (06/07/2016)

Small cell lung cancer (SCLC) accounts for approximately 20–25% of all lung cancers. SCLC is an aggressive and fast-growing type of cancer that is very responsive to chemotherapy. However, although initial anticancer responses to chemotherapy may be substantial, long-term survival for patients with SCLC remains poor. Survival in SCLC is no more than 15%, 2 … Continue reading "First Targeted Therapy Shows Promise in Small Cell Lung Cancer"